Literature DB >> 16336212

Class II phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle.

Yu Wang1, Kazuaki Yoshioka, Mohammed Ali Azam, Noriko Takuwa, Sotaro Sakurada, Yuji Kayaba, Naotoshi Sugimoto, Isao Inoki, Takaharu Kimura, Tomoyuki Kuwaki, Yoh Takuwa.   

Abstract

We demonstrated previously that membrane depolarization and excitatory receptor agonists such as noradrenaline induce Ca2+-dependent Rho activation in VSM (vascular smooth muscle), resulting in MP (myosin phosphatase) inhibition through the mechanisms involving Rho kinase-mediated phosphorylation of its regulatory subunit MYPT1. In the present study, we show in de-endothelialized VSM strips that the PI3K (phosphoinositide 3-kinase) inhibitors LY294002 and wortmannin inhibited KCl membrane depolarization- and noradrenaline-induced Rho activation and MYPT1 phosphorylation, with concomitant inhibition of MLC (20-kDa myosin light chain) phosphorylation and contraction. LY294002 also augmented de-phosphorylation of MLC and resultantly relaxation in KCl-contracted VSM, whereas LY294002 was much less effective or ineffective under the conditions in which MP was inhibited by either a phosphatase inhibitor or a phorbol ester in Rho-independent manners. VSM express at least four PI3K isoforms, including the class I enzymes p110alpha and p110beta and the class II enzymes PI3K-C2alpha and -C2beta. The dose-response relationships of PI3K-inhibitor-induced inhibition of Rho, MLC phosphorylation and contraction were similar to that of PI3K-C2alpha inhibition, but not to that of the class I PI3K inhibition. Moreover, KCl and noradrenaline induced stimulation of PI3K-C2alpha in a Ca2+-dependent manner, but not of p110alpha or p110beta. Down-regulation of PI3K-C2alpha expression by siRNA (small interfering RNA) inhibited contraction and phosphorylation of MYPT1 and MLC in VSM cells. Finally, intravenous wortmannin infusion induced sustained hypotension in rats, with inhibition of PI3K-C2alpha activity, GTP-loading of Rho and MYPT1 phosphorylation in the artery. These results indicate the novel role of PI3K-C2alpha in Ca2+-dependent Rho-mediated negative control of MP and thus VSM contraction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16336212      PMCID: PMC1383708          DOI: 10.1042/BJ20051471

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  Clostridium difficile toxin B inhibits carbachol-induced force and myosin light chain phosphorylation in guinea-pig smooth muscle: role of Rho proteins.

Authors:  C Lucius; A Arner; A Steusloff; M Troschka; F Hofmann; K Aktories; G Pfitzer
Journal:  J Physiol       Date:  1998-01-01       Impact factor: 5.182

2.  Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity.

Authors:  M Noda; C Yasuda-Fukazawa; K Moriishi; T Kato; T Okuda; K Kurokawa; Y Takuwa
Journal:  FEBS Lett       Date:  1995-07-03       Impact factor: 4.124

Review 3.  Signal transduction and regulation in smooth muscle.

Authors:  A P Somlyo; A V Somlyo
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

4.  Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin.

Authors:  J Domin; F Pages; S Volinia; S E Rittenhouse; M J Zvelebil; R C Stein; M D Waterfield
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

6.  Effects of a myosin light chain kinase inhibitor, wortmannin, on cytoplasmic Ca2+ levels, myosin light chain phosphorylation and force in vascular smooth muscle.

Authors:  M Takayama; H Ozaki; H Karaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

7.  Dynamics of myosin light chain phosphorylation at Ser19 and Thr18/Ser19 in smooth muscle cells in culture.

Authors:  K Sakurada; M Seto; Y Sasaki
Journal:  Am J Physiol       Date:  1998-06

8.  Wortmannin, a microbial product inhibitor of myosin light chain kinase.

Authors:  S Nakanishi; S Kakita; I Takahashi; K Kawahara; E Tsukuda; T Sano; K Yamada; M Yoshida; H Kase; Y Matsuda
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

9.  The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.

Authors:  S J Turner; J Domin; M D Waterfield; S G Ward; J Westwick
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

10.  Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction.

Authors:  H Yano; T Agatsuma; S Nakanishi; Y Saitoh; Y Fukui; Y Nonomura; Y Matsuda
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

View more
  35 in total

1.  Glucose-6-phosphate dehydrogenase is a regulator of vascular smooth muscle contraction.

Authors:  Rakhee S Gupte; Hirotaka Ata; Dhawjbahadur Rawat; Madoka Abe; Mark S Taylor; Rikuo Ochi; Sachin A Gupte
Journal:  Antioxid Redox Signal       Date:  2010-10-25       Impact factor: 8.401

Review 2.  A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic depolarization-induced vascular smooth muscle contraction.

Authors:  Ryan D Mills; Mitsuo Mita; Michael P Walsh
Journal:  J Muscle Res Cell Motil       Date:  2015-07-07       Impact factor: 2.698

Review 3.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

Review 4.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

5.  Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function.

Authors:  Kazuaki Yoshioka; Kotaro Yoshida; Hong Cui; Tomohiko Wakayama; Noriko Takuwa; Yasuo Okamoto; Wa Du; Xun Qi; Ken Asanuma; Kazushi Sugihara; Sho Aki; Hidekazu Miyazawa; Kuntal Biswas; Chisa Nagakura; Masaya Ueno; Shoichi Iseki; Robert J Schwartz; Hiroshi Okamoto; Takehiko Sasaki; Osamu Matsui; Masahide Asano; Ralf H Adams; Nobuyuki Takakura; Yoh Takuwa
Journal:  Nat Med       Date:  2012-09-16       Impact factor: 53.440

6.  Failure of Bay K 8644 to induce RhoA kinase-dependent calcium sensitization in rabbit blood vessels.

Authors:  S M Alvarez; A S Miner; B M Browne; P H Ratz
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.

Authors:  Shun Watanabe; Takayuki Matsumoto; Mirai Oda; Kosuke Yamada; Junya Takagi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2015-11-17       Impact factor: 3.657

8.  The SH3 domain of postsynaptic density 95 mediates inflammatory pain through phosphatidylinositol-3-kinase recruitment.

Authors:  Margaret I Arbuckle; Noboru H Komiyama; Ada Delaney; Marcelo Coba; Emer M Garry; Roberta Rosie; Andrew J Allchorne; Lynsey H Forsyth; Matthew Bence; Holly J Carlisle; Thomas J O'Dell; Rory Mitchell; Susan M Fleetwood-Walker; Seth G N Grant
Journal:  EMBO Rep       Date:  2010-05-14       Impact factor: 8.807

9.  Flavone Attenuates Vascular Contractions by Inhibiting RhoA/Rho Kinase Pathway.

Authors:  Inji Baek; Su Bun Jeon; Min-Ji Song; Enyue Yang; Uy Dong Sohn; In Kyeom Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-06-30       Impact factor: 2.016

10.  Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation.

Authors:  Rodrigo R Resende; Avishek Adhikari
Journal:  Cell Commun Signal       Date:  2009-08-27       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.